TY  - JOUR
A1  - Christl, Manfred
A1  - Lanzendörfer, Ulrike
A1  - Freund, Silke
T1  - Olefinadditionen an 2,5-Diphenyl-1,3,4-oxadiazin-6-on
N2  - No abstract available
Y1  - 1981
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-41525
N1  - Prof. Siegfried Hünig zum 60. Geburtstag gewidmet
ER  - 
TY  - JOUR
A1  - Wallstabe, Julia
A1  - Bussemer, Lydia
A1  - Groeber-Becker, Florian
A1  - Freund, Lukas
A1  - Alb, Mirian
A1  - Dragan, Mariola
A1  - Waaga-Gasser, Ana Maria
A1  - Jakubietz, Rafael
A1  - Kneitz, Hermann
A1  - Rosenwald, Andreas
A1  - Rebhan, Silke
A1  - Walles, Heike
A1  - Mielke, Stephan
T1  - Inflammation-Induced Tissue Damage Mimicking GvHD in Human Skin Models as Test Platform for Immunotherapeutics
JF  - ALTEX
N2  - Due to the rapidly increasing development and use of cellular products, there is a rising demand for non-animal-based test platforms to predict, study and treat undesired immunity. Here, we generated human organotypic skin models from human biopsies by isolating and expanding keratinocytes, fibroblasts and microvascular endothelial cells and seeding these components on a collagen matrix or a biological vascularized scaffold matrix in a bioreactor. We then were able to induce inflammation-mediated tissue damage by adding pre-stimulated, mismatched allogeneic lymphocytes and/or inflammatory cytokine-containing supernatants histomorphologically mimicking severe graft versus host disease (GvHD) of the skin. This could be prevented by the addition of immunosuppressants to the models. Consequently, these models harbor a promising potential to serve as a test platform for the prediction, prevention and treatment of GvHD. They also allow functional studies of immune effectors and suppressors including but not limited to allodepleted lymphocytes, gamma-delta T cells, regulatory T cells and mesenchymal stromal cells, which would otherwise be limited to animal models. Thus, the current test platform, developed with the limitation that no professional antigen presenting cells are in place, could greatly reduce animal testing for investigation of novel immune therapies.
KW  - inflammation-induced tissue demage
KW  - immunotherapeutics
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-229974
VL  - 37
IS  - 3
ER  -